Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data.

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Assignment of a patient to a specific therapeutic strategy has been already decided in the past according to normal routine clinical practice; the decision to prescribe a specific treatment (between January 2012 and December 2018) was clearly dissociated from the decision to include a patient in the present study.

The investigators will retrospectively collect the information for 500 patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable recurrent and/or metastatic disease, starting treatment with the defined cetuximab plus paclitaxel regimen, in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)", who express consent to participate in the study or have not explicitly withheld consent for use of their data. The information from the patients' medical records will be collected through the online database of the TTCC Group.

Study Overview

• Status: Completed
• Conditions: Squamous Cell Carcinoma of the Head and Neck
• Intervention / Treatment: Drug: Cetuximab; Drug: Paclitaxel

Detailed Description

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the restriction that the data collection will only be clinical data from patients who received paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab that could have been switched to biweekly during the maintenance phase.

The main objective will be to estimate the Progression-free survival (PFS) in patients treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have been switched to biweekly during the maintenance phase, as first line for recurrent and/or metastatic SCCHN.

Secondary objectives include:

To determine the Overall Response Rate (ORR), Best Overall Response (BOR), Disease Control Rate (DCR), overall survival (OS), duration of response (DoR), and safety in patients treated with the defined cetuximab plus paclitaxel regimen.

To evaluate the percentage of long disease-free survivors (defined as patients disease-free and alive at 2 years), and evaluate the percentage of long non-disease-free survivors (defined as patients not disease free, but alive at 2 years.

Analyses of patient outcomes by prognostic subgroups.

• Study Type: Observational
• Enrollment (Actual): 531

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain, 08003
    • Hospital de Mar
  • Madrid, Spain, 28041
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28040
    • Hospital Universitario Clínico San Carlos
  • Madrid, Spain, 28007
    • Hospital Universitario Gregorio Maranon
  • Andalucia
    • Granada, Andalucia, Spain, 18014
      • Hospital Universitario Virgen de las Nieves
    • Málaga, Andalucia, Spain, 29010
      • Hospital Regional Universitario de Malaga
    • Sevilla, Andalucia, Spain, 41014
      • Hospital Universitario Virgen de Valme
  • Aragon
    • Zaragoza, Aragon, Spain, 50009
      • Hospital Universitario Miguel Servet
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Hospital Universitario Marqués de Valdecilla
  • Castilla La Mancha
    • Toledo, Castilla La Mancha, Spain, 45004
      • Hospital Virgen de la Salud
  • Castilla Y Leon
    • Salamanca, Castilla Y Leon, Spain, 37007
      • Hospital Universitario de Salamanca
  • Cataluña
    • Badalona, Cataluña, Spain, 08916
      • Institut Catalá d'Oncologia (ICO) BADALONA
    • Girona, Cataluña, Spain, 17007
      • Institut Català d'Oncologia (ICO) Girona
    • Hospitalet de Llobregat, Cataluña, Spain, 08908
      • Hospital Duran i Reynalds (ICO-Hospitalet)
  • Comunitat Valenciana
    • Valencia, Comunitat Valenciana, Spain, 46026
      • Hospital Universitario y Politecnico La Fe
  • Galicia
    • A Coruña, Galicia, Spain, 15009
      • Centro Oncologico de Galicia
    • Lugo, Galicia, Spain, 27003
      • Hospital Universitario Lucus Augusti
  • Islas Baleares
    • Palma De Mallorca, Islas Baleares, Spain, 07120
      • Hospital Universitario Son Espases
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Complejo Hospitalario Navarra (PAMPLONA)
  • Tenerife
    • San Cristobal de la Laguna, Tenerife, Spain, 38320
      • Hospital Universitario Canarias (TENERIFE)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable R/M disease, starting treatment with the defined cetuximab plus paclitaxel regimen, between January 2012 and December 2018 in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello", who express consent to participate in the study or have not explicitly withheld consent for use of their data.

Description

Inclusion Criteria:

• Patients with histologically confirmed recurrent and/or metastatic head and neck squamous-cell carcinoma including oral cavity, oropharynx, hypopharynx and larynx.

Note: Histological confirmation is required at the diagnosis of the primary. Not for recurrence and/or metastatic stages when radiological or clinical confirmation is valid

• Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
• Start of first cycle of paclitaxel plus cetuximab between 1 January 2012, and 31 December 2018.
• Aged ≥ 18 years at the time of diagnosis of R/M SCCHN.

• Voluntary written consent, if applicable*

  • Note: Waiver of consent could be acceptable after all reasonable efforts and procedures have been followed and exhausted, and when an explicit refusal to sign the informed consent or refusal for use of data, or a revocation of consent by the patient has not been obtained.

Exclusion Criteria:

• Patients with histologically confirmed R/M SCCHN, who have also an unknown primary tumor or nasopharyngeal cancer or a non-squamous head & neck cancer.
• Patients who received the paclitaxel and cetuximab regimen for the first time in recurrent and/or metastatic disease as a second or subsequent line.
• Eastern Cooperative. Oncology Group (ECOG) performance status > 2.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Recurrent and/or metastatic SCCHN; Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.	Drug: Cetuximab; Weekly cetuximab at starting dose, that could be switched to biweekly; Drug: Paclitaxel; Paclitaxel at starting dose of 80 mg/m2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	The PFS time is defined as the time from start of study treatment (first administration of cetuximab or paclitaxel) to the date of progression or death, whichever occurs first. In patients without a PFS event, the PFS time will be censored on the date of the last radiological evaluation or on the date of the last study treatment received if the tumor response has not been evaluated after start of study treatment. If no PFS was observed prior to start of second line treatment, then the PFS time will be censored at the first date of second line treatment.	Through study completion, average 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best Overall Response (BOR)	Best overall response during study treatment with the categories complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) or not available (NA), as assessed by the responsible physician. The method used to assess BOR (e.g. RECIST and version) will be also recorded.	Through study completion, average 1 year
Overall Response Rate (ORR)	Overall response rate, defined as the proportion of patients with CR or PR as BOR.	Through study completion, average 1 year
Disease Control Rate (DCR)	The proportion of patients with CR, PR or SD as BOR.	Through study completion, average 1 year
Frequency of Adverse Events (AEs)	Safety will be studied as function of AEs frequency: The number of adverse events classified by type and intensity	Through study completion, average 1 year
Overall survival (OS)	Defined as time from start of study treatment until date of death due to any cause. In patients without death the OS time is censored at the last date known to be alive.	Through study completion, average 1 year
Relative dose intensity (RDI)	Relative dose intensity (RDI) defined as amount of drug administered per unit of time expressed as the fraction of that defined in the standard regimen	Through study completion, average 1 year
Dose-related and compliance data	Frequency and magnitude of dose interruptions, dose modifications and discontinuation of treatment classified by the cause of discontinuation including adverse events, relapse, medical decision, patient decision, death and loss of follow-up.	Through study completion, average 1 year
Duration of Response (DOR)	Defined as the time from the first occurrence of PR or CR as BOR until PD or death, whichever occurs first in patients with CR or PR as BOR. The censoring rules specified for PFS will be also applied for duration of response.	Through study completion, average 1 year
Proportion of long disease-free survivors	The proportion of patients alive and disease-free at 2 years after start of study treatment. Only disease-free patients under first line treatment should be counted.	Through study completion, average 1 year

Collaborators and Investigators

• Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
• Collaborators: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
• Investigators: Principal Investigator: Beatriz Cirauqui Cirauqui, M.D. Ph.D., Institut Catalá d'Oncologia (ICO) BADALONA; Principal Investigator: Jordi Rubió Casadevall, M.D. Ph.D., Institut Català d'Oncologia (ICO) Girona

Study record dates

Study Major Dates

• Study Start (Actual): December 18, 2020
• Primary Completion (Actual): January 17, 2022
• Study Completion (Actual): January 17, 2022

Study Registration Dates

• First Submitted: December 11, 2020
• First Submitted That Met QC Criteria: December 11, 2020
• First Posted (Actual): December 17, 2020

Study Record Updates

• Last Update Posted (Actual): March 23, 2022
• Last Update Submitted That Met QC Criteria: March 22, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Cetuximab; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; recurrent and/or metastatic; retrospective observational study
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Head and Neck Neoplasms; Neoplasms, Squamous Cell; Carcinoma; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Antineoplastic Agents, Immunological; Paclitaxel; Cetuximab
• Other Study ID Numbers: TTCC-2019-02; TTC-CET-2020-01 (Other Identifier: Agencia Española del Medicamento y Productos Sanitarios)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No